Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AMD (AMD) upgraded to Neutral from Sell at Goldman Sachs with analyst Toshiya Hari saying Intel's (INTC) struggles with 10nm process technology make it increasingly harder to argue for a bear thesis, even following the recent rally in the shares. 2. RBS (RBS) upgraded to Buy from Neutral at UBS with analyst Jason Napier saying the bank's capital strength is being undervalued by the market. 3. Dropbox (DBX) upgraded to Outperform from Sector Perform at RBC Capital with analyst Mark Mahaney citing "strong" Q2 results and above consensus guidance. 4. Sanofi (SNY) upgraded to Buy from Neutral at Citi. 5. Floor & Decor (FND) upgraded to Outperform from Market Perform at Wells Fargo with analyst Zachary Fadem saying he believes current share levels represent a "compelling long-term entry point for one of the best growth stories in all of retail." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Reports business EPS of EUR 1.78, down 17.6% reported and 7.4% at CER. Reports Q1 IRFS net sales EUR 10.464B, up 2.4%. Paul Hudson, Chief Executive Officer, commented: "We are off to an excellent start in 2024, delivering on our strategic priorities and a transformation of our portfolio of medicines and vaccines to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth. Continued strong performance by Dupixent and our new launches drove sales growth of seven percent. In parallel, we are delivering on our promise of increased investments in our late-stage pipeline to fully realize its value for patients and Sanofi. We are awaiting regulatory decisions for Dupixent in COPD, a progressive disease with limited effective treatment options. If approved, Dupixent will be the first biologic treatment in COPD. With the robust progress in our portfolio transformation, we reaffirm our financial guidance for 2024."